{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-036326","form_type":"8-K/A","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2026-08-06T19:45:05+00:00","discovered_at":"2026-08-06T19:46:01.553645+00:00","generated_at":"2026-08-06T19:46:08.092146+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ensysce acquires Cy Biopharma and up to $77M private financing for CRPS drug","bullets":["Acquisition of Cy Biopharma includes clinical-stage neuroplastogenic therapy CY200 for CRPS with FDA Orphan Drug Designation.","Up to $77M financing: $21.5M initial private placement, $17.1M from Cy Biopharma cash, plus $38.6M milestone tranche.","Pro forma cash expected to fund CY200 through Phase 2 proof-of-concept and into registrational development.","James Morrison, Cy Biopharma CEO, becomes President of Ensysce and joins Board of Directors.","Post-acquisition ownership: Cy Biopharma holders ~74.94%, Ensysce ~7.57%, new investors ~17.49%; combined equity value ~$122.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-036326","json":"https://secwatch.observer/filing/0001493152-26-036326.json","markdown":"https://secwatch.observer/filing/0001493152-26-036326.md","text":"https://secwatch.observer/filing/0001493152-26-036326.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226036326/0001493152-26-036326-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226036326/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T19:46:08.092146+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}